Zhejiang Hisun to handle work in China for Celsion's immuno-oncology therapy

China flag
China flag

Taizhou-based Zhejiang Hisun Pharmaceuticals will handle greater China development to commercialization on ovarian immuno-oncology prospect GEN-1 from Celsion in an expanded partnership aimed at lower costs and quicker approvals.

The effort includes a technology transfer agreement to Zhejiang Hisun, which has a joint venture with Pfizer ($PFE) in China, Hisun-Pfizer Pharmaceuticals. The company is currently facing heat from U.S. FDA for manufacturing violations.

In a release, Celsion said the mediated, IL-12 immunotherapy pact would start with greater China--which includes Hong Kong and Macau--and possibly expand if regulatory approvals are obtained.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Financial terms were not detailed, but Celsion said the expanded agreement is aimed at lower costs for clinical supplies of GEN-1 compared to current providers. In return, Zhejiang Hisun would receive an unspecified percentage of China’s commercial unit demand, as well as global commercial unit demand, if the candidate reaches approval.

"The agreement will help to support supply for both ongoing and planned clinical studies in the United States, and for potential future studies of GEN-1 in China," the release said.

In March, Celsion announced an Optima study in China related to its ThermoDox candidate via work with Hisun, which it said in the release was possibly key for regulatory approval. The same focus applies to GEN-1.

"Hisun’s expertise may provide an advantage when seeking China Food and Drug Administration approval," Michael H. Tardugno, chairman, CEO and president, said in a statement.

- here's the release

Related Articles:
U.S. FDA ingredient exceptions from banned Zhejiang Hisun plant draw scrutiny

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.